Germantown’s QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT SA

by MCS Staff

Earlier this month, QIAGEN N.V.  (which has its United States headquarters in Germantown) announced that it signed agreements to acquire a 96% majority ownership stake in BLIRT SA (Polish Stock Exchange: BLR), a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. 

Per the press release: BLIRT develops, manufactures and commercializes standardized and customized solutions for proteins and enzymes as well as molecular biology reagents. Its offering includes proteins and enzymes that are critical to the life sciences industry and diagnostic kit manufacturers, especially for non-COVID-19 applications. BLIRT, founded in 1994 in Gdansk, Poland, has approximately 90 employees and generated 2021 sales of less than $10 million.

“The addition of BLIRT to QIAGEN brings highly complementary capabilities that will create additional growth prospects for our enzymes and reagents business,” said Thomas Schweins, Senior Vice President and Head of QIAGEN’s Life Sciences Business Area. “BLIRT will also widen our geographic presence, add new sales channels, strengthen our production and R&D capacities and safeguard our supply chains. This acquisition will further strengthen our sample technologies business, one of our five pillars of growth. And it also supports our strategy to focus on attractive growth opportunities in the life science and molecular diagnostic markets and our disciplined approach to value-creating acquisitions.”

“Over recent years, we have intensively grown our business: we have invested, observed trends and found new markets”, said Marian Popinigis, CEO of BLIRT SA. “Thanks to QIAGEN, the growth of BLIRT will accelerate. First and foremost, the scale of operations will increase, and our employees will become part of a global team. We accepted QIAGEN’s offer because it would benefit everyone involved: both companies, customers, distributors and employees. I am confident that we will observe positive synergy effects from the joint operations of QIAGEN and BLIRT in the upcoming years. This will create exciting new possibilities. Among other things, customers will have access to a broader offer, and employees will take advantage of new career options.”

Under the terms of the agreement, QIAGEN has acquired more than 96% of the outstanding shares of BLIRT in transactions with a group of leading shareholders. QIAGEN intends to obtain full ownership of BLIRT, which will be fully consolidated by QIAGEN following the closing of the transaction in the second quarter of 2022. The acquisition of BLIRT does not have any material impact on QIAGEN’s financial outlook for 2022, as announced on April 26, 2022.

For more information, please visit


You may also like

Leave a Comment


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy